Drug
safety advice |
|
Citalopram
and escitalopram: QT interval prolongationnew maximum daily
dose restrictions (including in elderly patients), contraindications,
and warnings
|
|
Dabigatran
(Pradaxa): risk of serious haemorrhage¡ªneed for renal
function testing |
Hot
topics |
|
Angiotensin
II receptor antagonists: evidence does not suggest any link with cancer |
Other
information from the MHRA |
|
Learning
about reducing medicines risk |
End-of-year
quiz |
|
Test
your drug-safety knowledge |